Read by QxMD icon Read

Vaginal atrophy

Kelly M Tucker, Keshav Godha, Sebastian Mirkin, David F Archer
OBJECTIVE: The aim of the study was to determine the utility of vaginal pH as a marker of menopause and vulvar and vaginal atrophy (VVA) before and after local estrogen treatment. METHODS: Vaginal pH was determined using standard pH paper strips in two clinical trials involving postmenopausal women with signs and symptoms of VVA evaluated before and after intervention with vaginal estradiol in softgel capsules. The utility of vaginal pH was evaluated as a screening method for VVA due to menopause and correlations were analyzed between vaginal pH and VVA symptoms, physical changes, and maturation of the vaginal epithelium...
March 5, 2018: Menopause: the Journal of the North American Menopause Society
Mauricio Plata, Daniela Robledo, Alejandra Bravo-Balado, Juan Carlos Castaño, Catalina Osorio, Milton Salazar, Juan Guillermo Velásquez, Carlos Gustavo Trujillo, Juan Ignacio Caicedo, Juan Guillermo Cataño
INTRODUCTION AND HYPOTHESIS: We report our experience with the Remeex system™ in women with recurrent stress urinary incontinence (SUI) or intrinsic sphincter deficiency (ISD). METHODS: A multicenter retrospective study was conducted in women who underwent an adjustable sling procedure between 2011 and 2016. We used urodynamic studies (UDS) preoperatively and the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and cough stress test (CST) pre- and postoperatively...
March 3, 2018: International Urogynecology Journal
A R Mothes, M Runnebaum, I B Runnebaum
PURPOSE: First evaluation of dual-phase vaginal Er:YAG laser to omit hormonal treatment for atrophy-related symptoms in post-menopausal breast cancer survivors following prolapse surgery. METHODS: Patients with a history of breast cancer at the time of surgery for pelvic organ prolapse were offered non-hormonal vaginal Er:YAG laser treatment when complaining of atrophy-related genitourinary syndrome of menopause. A single 10-min course of dual-phase protocol of pulsed Er:YAG laser (2940 nm, fractional ablative and thermal mode, fluence according to tissue thickness)...
February 27, 2018: Journal of Cancer Research and Clinical Oncology
Michele Carlo Schiavi, Valentina Sciuga, Andrea Giannini, Flaminia Vena, Ottavia D'oria, Giovanni Prata, Chiara Di Tucci, Delia Savone, Natalia Aleksa, Carmela Capone, Daniele Di Mascio, Maria Letizia Meggiorini, Marco Monti, Marzio Angelo Zullo, Ludovico Muzii, Pierluigi Benedetti Panici
The aim of this study was to assess the effectiveness of ospemifene in the improvement of sexual function in postmenopausal women with vulvovaginal atrophy (VVA) affected by overactive bladder syndrome (OAB) or urge urinary incontinence (UUI). One hundred five postmenopausal patients with VVA affected by OAB and/or UUI were enrolled for the study. All patients received ospemifene 60 mg for 12 weeks. Clinical examination, 3-d voiding diary and the vaginal health index (VHI) were performed at baseline and at 12 weeks...
February 20, 2018: Gynecological Endocrinology
Tatiane Fernandes, Adriana O Pedro, Luiz F Baccaro, Lucia H Costa-Paiva
OBJECTIVE: The aim of the study was to evaluate the laboratory and endometrial safety of topical testosterone versus topical estrogen for the treatment of vaginal atrophy in postmenopausal women. METHODS: This was a randomized, placebo-controlled trial of 60 postmenopausal women aged 40 to 70 years at the Menopause Clinic of CAISM UNICAMP. Women were randomized into three vaginal treatment groups: estrogen, testosterone, or placebo. The treatment was applied 3 times a week for 12 weeks...
February 16, 2018: Menopause: the Journal of the North American Menopause Society
Antonio Simone Laganà, Salvatore Giovanni Vitale, Lily Stojanovska, Irene Lambrinoudaki, Vasso Apostolopoulos, Benito Chiofalo, Laura Rizzo, Francesca Basile
This single-arm pilot study enrolled 47 post-menopausal women affected by vulvovaginal atrophy (VVA). The Vaginal Health Index Score (VHIS) was evaluated for all women and all completed the Female Sexual Function Index (FSFI) questionnaire at baseline (T0) and after 15 days of vaginal cream treatment with one application per day (T1). Following treatment there was a significant improvement in all VHIS parameters and total score (p < 0.0001). Similarly, there was a significant improvement on four FSFI domains (lubrication, orgasm, satisfaction and pain) and total score (p = 0...
March 2018: Maturitas
Jennifer L Marino, Helen C McNamara, Martha Hickey
Impaired ovarian function and menopausal symptoms are common after cancer treatment. Menopausal symptoms often occur at an earlier age in women with cancer, and may be more severe than in natural menopause; they may be the most persistent and troubling sequelae of cancer. A third of female patients with cancer report dissatisfaction with the quality and length of physician-patient discussions about reproductive health, including menopause. Systemic menopausal hormone therapy is the most effective treatment for menopausal symptoms, but it is not suitable for all patients after cancer - where it is unsuitable, alternative effective non-hormonal treatments are available...
February 19, 2018: Medical Journal of Australia
G A Casarotti, P Chiodera, C Tremolada
OBJECTIVE: Urogenital atrophy is a degenerative process that may occur during menopause causing debilitating disorders and painful symptomatology. Estrogen therapy slows the onset of atrophy, but it requires ongoing therapy to maintain its effectiveness. To mitigate the degenerative evolutions associated with menopause, patients may benefit from new therapeutic approaches, such as the use of mesenchymal stem cells. Among the many sources, the adipose tissue is considered one of the smartest, due to its abundance and easy access...
January 2018: European Review for Medical and Pharmacological Sciences
E Moral, J L Delgado, F Carmona, B Caballero, C Guillán, P M González, J Suárez-Almarza, S Velasco-Ortega, C Nieto
OBJECTIVE: To determine the prevalence of genitourinary syndrome of menopause (GSM) and urogynecological conditions associated with menopause, and to evaluate the impact of GSM on quality of life in a cohort of Spanish postmenopausal women. METHODS: Multicenter, cross-sectional, and observational study involving 430 women. RESULTS: The prevalence of GSM was 70%. GSM was diagnosed in 60.2% of women with no known diagnosis of vulvovaginal atrophy or GSM...
February 7, 2018: Climacteric: the Journal of the International Menopause Society
Jacek Krzysztof Szymański, Bogumił Paweł Siekierski, Anna Kajdy, Grzegorz Jakiel
Sex hormone deficiency in post-menopausal women causes changes in the lower urinary tract. Vulvovaginal atrophy is a pathology resulting from those changes. VVA has a negative effect on the quality of life therefore prompting a search for new therapeutic options. The aim of this article is to summarize the current treatment modalities, both hormonal and non-hormonal for post-menopausal vaginal atrophy. Topical oestrogen therapy remains the "golden standard". Alternatives, although promising, require well-designed control studies...
2018: Ginekologia Polska
James M Weinberger, Justin Houman, Ashley T Caron, Jennifer Anger
BACKGROUND: Female sexual dysfunction (FSD) is a highly prevalent condition. Nevertheless, the scientific literature has only recently begun to accumulate evidence for treatment modalities that address the underlying etiologies of FSD. AIM: The purpose of this systematic review is to elucidate what treatments are effective across the various symptom complexes of FSD. METHODS: Utilizing Meta-analysis of Observational Studies in Epidemiology guidelines, we conducted a systematic review of PubMed, EMBASE, clinicaltrials...
February 3, 2018: Sexual Medicine Reviews
A O Mueck, X Ruan, V Prasauskas, P Grob, O Ortmann
In recent years, a vast quantity of clinical data has been accumulated on the pathophysiology of symptomatic vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) in peri- and postmenopausal women and on the treatment options for these conditions. Guidelines from several societies have recently been updated in favor of VVA/GSM vaginal therapy with the lowest possible doses of estrogens. The combination of a vaginal ultra-low dose of 0.03 mg of estriol (E3) and lyophilized, viable Lactobacillus acidophilus KS400 (0...
January 30, 2018: Climacteric: the Journal of the International Menopause Society
Maria Grazia Matarazzo, Salvatore Caruso, Giuliana Giunta, Gaetano Valenti, Giuseppe Sarpietro, Antonio Cianci
OBJECTIVES: OAB is a common finding in postmenopausal women. Hypoestrogenism is the root cause of many signs and symptoms of Genitourinary Syndrome of Menopause (vaginal dryness, atrophy, dyspareunia, urinary disorders, etc.). As such the aim of this study was to evaluate the urodynamic effects of ultralowdose estriol vaginal gel formulation to treat women with Genitourinary Syndrome of Menopause and Overactive Bladder Syndrome. STUDY DESIGN: This open-labeled, single center, prospective study involved 37 women with OAB recruited in our Urogynecological Unit between January and July 2016...
March 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
H A Torky, A Taha, H Marie, E El-Desouky, O Raslan, A A Moussa, A M Ahmad, A Abo-Louz, S Zaki, T Fares, A Eesa
OBJECTIVE AND DESIGN: Prospective randomized controlled trial to test the effectiveness of topical oxytocin gel to improve vaginal atrophy in postmenopausal women. PATIENTS AND METHODS: A total of 140 postmenopausal women presenting with vaginal atrophy and who satisfied the inclusion and exclusion criteria were randomized into two groups each of 70 patients; they received intravaginal oxytocin gel or placebo gel for 30 days. Serum estrogen level, visual, colposcopic and histological vaginal examination were performed before and after treatment...
January 19, 2018: Climacteric: the Journal of the International Menopause Society
Miranda A Farage, Tom Cambron, Kan-Zhi Liu
Background: A clinical study was conducted to evaluate the feasibility of using visible and near-infrared (NIR) spectroscopy as a potential noninvasive measure of genital skin health in premenopausal and postmenopausal women. Methods: A total of 45 female subjects (aged 21-70 years), all of whom gave fully informed consent to participate, were enrolled in the study and assigned to 1 of 3 groups: 15 premenopausal (Pre-M), 15 postmenopausal receiving hormone replacement therapy (Post-M HRT), and 15 postmenopausal receiving no form of hormone replacement therapy (Post-M non-HRT)...
2018: Clinical Medicine Insights. Women's Health
Salvatore Caruso, Stefano Cianci, Valentina Fava, Agnese M C Rapisarda, Silvia Cutello, Antonio Cianci
OBJECTIVE: The aim of the study was to evaluate the effects of nutraceuticals containing equol on vaginal health of postmenopausal women with vulvovaginal symptoms and dyspareunia. METHODS: One hundred twenty-six natural postmenopausal women on +1b +1c (2 and 3-6 y after the final menstrual period, respectively) of the Stages of Reproductive Aging Workshop were enrolled in a nonrandomized trial. Of these, 72 women accepted to use nutraceutical (group A). The remaining 54 women refused the treatment and participated as the control group (group B)...
January 8, 2018: Menopause: the Journal of the North American Menopause Society
Federica Palma, Anjeza Xholli, Angelo Cagnacci
OBJECTIVES: Vaginal atrophy (VA) is a chronic medical condition. It is managed unsatisfactorily, despite its high prevalence and negative impact on female quality of life. In order to meet their needs, it would be useful to know what women perceive to be the most bothersome symptom (MBS) of VA. STUDY DESIGN: Cross-sectional, multicenter study of 913 postmenopausal women consulting 22 gynecological outpatient services. MAIN OUTCOME MEASURES: Prevalence of the MBS perceived by postmenopausal women of different age and vaginal condition...
February 2018: Maturitas
Robin J Bell, Farwa Rizvi, Rakabul M Islam, Susan R Davis
OBJECTIVES: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support efficacy and safety of intravaginal testosterone for the treatment of VVA. METHODS: Scopus, MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched on July 26, 2017, for human studies published in English of clinical trials of intravaginal testosterone...
December 28, 2017: Menopause: the Journal of the North American Menopause Society
Tiziana Pagano, Pasquale De Rosa, Roberta Vallone, Francesco Schettini, Grazia Arpino, Mario Giuliano, Rossella Lauria, Irene De Santo, Alessandro Conforti, Alessandra Gallo, Giovanni Nazzaro, Sabino De Placido, Mariavittoria Locci, Giuseppe De Placido
OBJECTIVE: Vulvovaginal atrophy (VVA) is a condition frequently observed in menopause. Its symptoms can significantly affect the quality of life of patients. Since VVA is related to estrogen deficiency, chemotherapy and hormone therapy for breast cancer (BC) might cause VVA by inducing menopause. Given the lack of effective treatment for VVA in BC survivors, we retrospectively evaluated the efficacy and tolerability of fractional microablative CO2 laser therapy in these patients. METHODS: We treated 82 BC survivors with three cycles of CO2 laser after failure of topical nonestrogenic therapy...
December 28, 2017: Menopause: the Journal of the North American Menopause Society
Sônia Maria Rolim Rosa Lima, Adriana Bittencourt Campaner, Antonio Pedro Flores Auge
No abstract text is available yet for this article.
September 2017: Revista da Associação Médica Brasileira
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"